364 related articles for article (PubMed ID: 28614980)
41. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.
Holmes FA; O'Shaughnessy JA; Vukelja S; Jones SE; Shogan J; Savin M; Glaspy J; Moore M; Meza L; Wiznitzer I; Neumann TA; Hill LR; Liang BC
J Clin Oncol; 2002 Feb; 20(3):727-31. PubMed ID: 11821454
[TBL] [Abstract][Full Text] [Related]
42. Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in 2489 cancer patients: final results from the non-interventional study NADIR.
Fietz T; Lück A; Schulz H; Harde J; Losem C; Grebhardt S; Wolff T; Potthoff K; Müller U; Zaiss M; Kurbacher CM
Curr Med Res Opin; 2019 Jul; 35(7):1127-1138. PubMed ID: 30557099
[No Abstract] [Full Text] [Related]
43. Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.
Heaney ML; Toy EL; Vekeman F; Laliberté F; Dority BL; Perlman D; Barghout V; Duh MS
Cancer; 2009 Oct; 115(20):4839-48. PubMed ID: 19637341
[TBL] [Abstract][Full Text] [Related]
44. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta).
Molineux G
Curr Pharm Des; 2004; 10(11):1235-44. PubMed ID: 15078138
[TBL] [Abstract][Full Text] [Related]
45. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma.
Vose JM; Crump M; Lazarus H; Emmanouilides C; Schenkein D; Moore J; Frankel S; Flinn I; Lovelace W; Hackett J; Liang BC
J Clin Oncol; 2003 Feb; 21(3):514-9. PubMed ID: 12560443
[TBL] [Abstract][Full Text] [Related]
46. An analysis of current neutropenia therapies, including pegfilgrastim.
Gabrilove JL
Clin Cornerstone; 2006; 8 Suppl 5():S19-28. PubMed ID: 17379160
[TBL] [Abstract][Full Text] [Related]
47. Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer.
Akpo EIH; Jansen IR; Maes E; Simoens S
Front Pharmacol; 2017; 8():614. PubMed ID: 28955224
[No Abstract] [Full Text] [Related]
48. Lipegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in Dutch patients.
Timmer-Bonte JNH; Ouwerkerk J; Faber LM; Kerkhofs LGM; Laterveer L; Ten Oever D; van Rees BP; van der Linden PW
Neth J Med; 2020 Sep; 78(5):270-276. PubMed ID: 33093252
[TBL] [Abstract][Full Text] [Related]
49. Pegfilgrastim-jmdb/MYL-1401H: A Pegfilgrastim Biosimilar.
Hoy SM
BioDrugs; 2019 Feb; 33(1):117-120. PubMed ID: 30701419
[TBL] [Abstract][Full Text] [Related]
50. The Effectiveness of Febrile Neutropenia Prophylaxis with Lipegfilgrastim in Routine Clinical Practice.
Holubec L; Polivka J; Lisnerova L; Kubikova T; Safanda M
In Vivo; 2017; 31(3):303-306. PubMed ID: 28438855
[TBL] [Abstract][Full Text] [Related]
51. Effect of lipegfilgrastim administration as prophylaxis of chemotherapy-induced neutropenia on dose modification and incidence of neutropenic events: real-world evidence from a non-interventional study in Belgium and Luxembourg.
Fontaine C; Claes N; Graas MP; Samani KK; Vuylsteke P; Vulsteke C
Acta Clin Belg; 2021 Feb; 76(1):10-15. PubMed ID: 31399016
[No Abstract] [Full Text] [Related]
52. Pegfilgrastim.
Willis F; Pettengell R
Expert Opin Biol Ther; 2002 Dec; 2(8):985-92. PubMed ID: 12517276
[TBL] [Abstract][Full Text] [Related]
53. A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09.
Lee KH; Kim JY; Lee MH; Han HS; Lim JH; Park KU; Park IH; Cho EK; Yoon SY; Kim JH; Choi IS; Park JH; Choi YJ; Kim HJ; Jung KH; Kim SY; Oh DY; Im SA
Support Care Cancer; 2016 Apr; 24(4):1709-17. PubMed ID: 26423618
[TBL] [Abstract][Full Text] [Related]
54. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.
Perrier L; Lefranc A; Pérol D; Quittet P; Schmidt-Tanguy A; Siani C; de Peretti C; Favier B; Biron P; Moreau P; Bay JO; Lissandre S; Jardin F; Espinouse D; Sebban C
Appl Health Econ Health Policy; 2013 Apr; 11(2):129-38. PubMed ID: 23435861
[TBL] [Abstract][Full Text] [Related]
55. Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia.
Crawford J
Drugs; 2002; 62 Suppl 1():89-98. PubMed ID: 12479597
[TBL] [Abstract][Full Text] [Related]
56. Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy.
Weycker D; Malin J; Barron R; Edelsberg J; Kartashov A; Oster G
Am J Clin Oncol; 2012 Jun; 35(3):267-74. PubMed ID: 21378538
[TBL] [Abstract][Full Text] [Related]
57. [Lipegfilgrastim - long acting G-CSF in prevention of chemotherapy-induced neutropenia].
Gálffy G
Magy Onkol; 2018 Sep; 62(3):195-200. PubMed ID: 30256886
[TBL] [Abstract][Full Text] [Related]
58. Neutropenia-Associated Outcomes in Patients With Breast Cancer Receiving Myelosuppressive Chemotherapy With Reduced Doses of Pegfilgrastim.
Moore DC; Gebru T; Pellegrino A; Fasan A; Patel J; Ringley JT
J Pharm Pract; 2020 Dec; 33(6):779-783. PubMed ID: 30917723
[TBL] [Abstract][Full Text] [Related]
59. A pilot study on intermittent every other days of 5-dose Filgrastim compared with single Pegfilgrastim in breast Cancer patients receiving adjuvant Docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy.
Sohn BS; Jeong JH; Ahn JH; Jung KH; Kim JE; Sohn JH; Koh SJ; Seo JH; Lee KS; Kim SB
Invest New Drugs; 2020 Jun; 38(3):866-873. PubMed ID: 31728715
[TBL] [Abstract][Full Text] [Related]
60. Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults With Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
Blayney DW; Zhang Q; Feng J; Zhao Y; Bondarenko I; Vynnychenko I; Kovalenko N; Nair S; Ibrahim E; Udovista DP; Mohanlal R; Ogenstad S; Ette E; Du L; Huang L; Shi YK
JAMA Oncol; 2020 Nov; 6(11):e204429. PubMed ID: 32970104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
